IL6 and Insulin resistance: IL-6 has three signaling modalities, referred to as “trans-signaling” (where IL-6 uses the soluble form of the IL-6Rα as a receptor), activation via JAK/STAT intracellular mediators, leading to hepatic and systemic inflammatory responses, endothelial proinflammatory changes [87,90,91,92] and inducing insulin resistance, acute liver damage, regeneration, and chronic liver inflammation [92].